Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Some sort of "pharmacy intervention" could aid switches, CEO Hendrickson says; board bloc is still pushing to divest the generic Rx segment but apparent second-quarter sales validation isn't enough to persuade Hendrickson to stay on.